Barriers to effective TRAIL-targeted therapy of malignancy [7]

Journal of Clinical Oncology

Volumn 25, Issue 28, 2007, Pages 4505-4506

  Dyer, Martin J S ^a   MacFarlane, Marion ^a   Cohen, Gerald M ^a  

^a MRC TOXICOLOGY UNIT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DEATH RECEPTOR 4; DEATH RECEPTOR 5; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; MAPATUMUMAB; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER THERAPY; CHRONIC LYMPHATIC LEUKEMIA; IMMUNOHISTOCHEMISTRY; LETTER; MALIGNANT MENINGIOMA; MEDULLOBLASTOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; ANIMAL; DRUG POTENTIATION; DRUG RESISTANCE; DRUG TOXICITY; HUMAN; MOUSE; NEOPLASM; NOTE;

ANIMALS; ANTIBODIES, MONOCLONAL; DRUG RESISTANCE, NEOPLASM; DRUG TOXICITY; HUMANS; MICE; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 35348877298     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.13.1011     Document Type: Letter

References (10)

1. Tolcher AW, Mita M, Meropol NJ, et al: Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol 25:1390-1395, 2007
2. Gajewski TF: On the TRAIL toward death receptor-based cancer therapeutics. J Clin Oncol 25:1305-1307, 2007
3. MacFarlane M, Harper N, Snowden RT, et al: Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene 21:6809-6818, 2002
4. Inoue S, MacFarlane M, Harper N, et al: Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11:S193-206, 2004 (suppl 2)
5. MacFarlane M, Inoue S, Kohlhaas SL, et al: Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1. Cell Death Differ 12:773-782, 2005
6. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, et al: TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res 65:11265-11270, 2005
7. Panner A, James CD, Berger MS, et al: mTOR controls FLIPS translation and TRAIL sensitivity in glioblastoma multiforme cells. Mol Cell Biol 25:8809-8823, 2005
8. Koschny R, Holland H, Sykora J, et al: Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 13:3403-3412, 2007
9. Koschny R, Walczak H, Ganten TM: The promise of TRAIL: Potential and risks of a novel anticancer therapy. J Mol Med doi:10.1007/s00109-007-0194-1
10. Inoue S, Mai A, Dyer MJS, et al: Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 66:6785-6792, 2006